{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:13:07Z","timestamp":1779297187308,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233237"],"award-info":[{"award-number":["UG1CA233237"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189859"],"award-info":[{"award-number":["UG1CA189859"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233234"],"award-info":[{"award-number":["UG1CA233234"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233196"],"award-info":[{"award-number":["UG1CA233196"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233330"],"award-info":[{"award-number":["UG1CA233330"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA232760"],"award-info":[{"award-number":["UG1CA232760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233320"],"award-info":[{"award-number":["UG1CA233320"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA233290"],"award-info":[{"award-number":["UG1CA233290"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189953"],"award-info":[{"award-number":["UG1CA189953"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100194","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:06:26Z","timestamp":1768388786000},"page":"100194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James M.","family":"Foran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-534X","authenticated-orcid":false,"given":"Zhuoxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janis","family":"Racevskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-628X","authenticated-orcid":false,"given":"Fran","family":"Garrett-Bakelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Randolph","family":"Broun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-8198","authenticated-orcid":false,"given":"Kristen Marie","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bneo.2026.100194_bib1","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100194_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V86.2.457.bloodjournal862457","article-title":"A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)","volume":"86","author":"Rowe","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100194_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100194_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100194_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.bneo.2026.100194_bib6","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2026.100194_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100194_bib8","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2026.100194_bib9","first-page":"324","article-title":"Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia","volume":"88","author":"Lindemalm","year":"2003","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.bneo.2026.100194_bib10","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias","volume":"9","author":"Gandhi","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2026.100194_bib11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2026.100194_bib12","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2009.26.4242","article-title":"European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy","volume":"28","author":"Burnett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100194_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2009.23.3130","article-title":"Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2026.100194_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100194_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100194_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100194_bib17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100194_bib18","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2026.100194_bib19","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.bneo.2026.100194_bib20","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100194_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.0006-341X.2004.00160.x","article-title":"Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials","volume":"60","author":"Wahed","year":"2004","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.bneo.2026.100194_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.0006-341X.2002.00048.x","article-title":"Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials","volume":"58","author":"Lunceford","year":"2002","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.bneo.2026.100194_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1541-0420.2007.00707.x","article-title":"Cox regression methods for two-stage randomization designs","volume":"63","author":"Lokhnygina","year":"2007","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.bneo.2026.100194_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses","volume":"40","author":"Norsworthy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bneo.2026.100194_bib25","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100194_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/leu.2016.225","article-title":"A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia","volume":"31","author":"Burnett","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2026.100194_bib27","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100194_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/hematology.2020000098","article-title":"Updates in infection risk and management in acute leukemia","volume":"2020","author":"Logan","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.bneo.2026.100194_bib29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100194_bib30","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.bneo.2026.100194_bib31","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100194_bib32","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"23","key":"10.1016\/j.bneo.2026.100194_bib33","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bneo.2026.100194_bib34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2026.100194_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10388","key":"10.1016\/j.bneo.2026.100194_bib36","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bneo.2026.100194_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100194_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100194_bib39","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.bneo.2026.100194_bib40","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bneo.2026.100194_bib41","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100194_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/bjh.17523","article-title":"Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia","volume":"194","author":"Wiernik","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100194_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jgo.2020.10.004","article-title":"Validation of the \"fitness criteria\" for the treatment of older patients with acute myeloid leukemia: a multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)","volume":"12","author":"Borlenghi","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100194_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-022-00700-x","article-title":"A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries","volume":"12","author":"Berard","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:20Z","timestamp":1779294440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000051"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100194","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100194"}}